UTMD UTAH MEDICAL PRODUCTS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 706698 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.6%
TTM net income YoY-8.4%
TTM EPS YoY-5.6%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR-14.3%
Margins
Gross margin57.7%
Operating margin29.9%
Net margin30.5%
FCF margin31.1%
EBITDA margin32.4%
Returns
ROE8.8%
ROA8.5%
ROIC (approx.)23.7%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets4.1%
Debt / equity0.00x
Current ratio21.23x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.08x
Accruals ratio-0.7%
Payout ratio37.0%
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $38.52M | $40.90M | $50.22M | $52.28M | $49.05M |
| Cost of revenue | $16.52M | $16.76M | $20.19M | $20.09M | $18.14M |
| Gross profit | $22.00M | $24.14M | $30.04M | $32.20M | $30.92M |
| R&D expense | $668,000 | $813,000 | $560,000 | $493,000 | $526,000 |
| SG&A expense | $7.88M | $7.83M | $11.02M | $10.41M | $10.10M |
| Operating income | $11.40M | $13.59M | $16.78M | $19.79M | $18.88M |
| Pretax income | $14.11M | $16.80M | $20.09M | $20.66M | $19.06M |
| Income tax | $2.82M | $2.93M | $3.45M | $4.19M | $4.27M |
| Net income | $11.29M | $13.87M | $16.64M | $16.47M | $14.79M |
| EBITDA | $12.23M | $14.32M | $17.40M | $20.40M | $19.52M |
| EPS (basic) | 3.48 | 3.96 | 4.58 | 4.53 | 4.05 |
| EPS (diluted) | 3.48 | 3.96 | 4.57 | 4.52 | 4.04 |
| Weighted avg. shares (diluted) | 3.24M | 3.50M | 3.64M | 3.64M | 3.66M |
| Balance sheet | |||||
| Cash & equivalents | $85.76M | $82.98M | $92.87M | $75.05M | $60.97M |
| Receivables | $3.52M | $4.09M | $3.39M | $5.54M | $5.13M |
| Inventory | $7.93M | $8.81M | $9.58M | $8.81M | $6.60M |
| Current assets | $97.74M | $96.33M | $106.27M | $89.92M | $73.16M |
| PP&E, net | $9.91M | $9.76M | $10.55M | $10.22M | $10.62M |
| Goodwill | $14.05M | $13.58M | $13.69M | $13.35M | $14.10M |
| Intangibles | $840,000 | $2.87M | $4.95M | $10.38M | $17.76M |
| Total assets | $122.54M | $122.54M | $135.46M | $123.87M | $115.64M |
| Current liabilities | $2.60M | $3.76M | $4.71M | $5.96M | $3.75M |
| Long-term debt | $225,000 | $282,000 | $295,000 | $0 | $0 |
| Total debt | $225,000 | $282,000 | $295,000 | $0 | $0 |
| Total liabilities | $3.27M | $5.11M | $7.14M | $9.62M | $8.50M |
| Shareholders' equity | $119.27M | $117.43M | $128.31M | $114.25M | $107.14M |
| Net debt | -$85.53M | -$82.69M | -$92.57M | -$75.05M | -$60.97M |
| Shares outstanding | 3.19M | 3.33M | 3.63M | 3.63M | 3.65M |
| Cash flow statement | |||||
| Operating cash flow | $14.69M | $14.83M | $22.28M | $21.15M | $21.20M |
| Capital expenditure | $371,000 | $230,000 | $639,000 | $809,000 | $552,000 |
| Free cash flow | $14.32M | $14.60M | $21.64M | $20.34M | $20.65M |
| Investing cash flow | -$371,000 | -$208,000 | -$639,000 | -$818,000 | -$552,000 |
| Financing cash flow | -$12.34M | -$23.84M | -$4.17M | -$5.48M | -$10.90M |
| Depreciation & amortization | $826,000 | $730,000 | $623,000 | $612,000 | $636,000 |
| Stock-based compensation | $373,000 | $256,000 | $225,000 | $183,000 | $166,000 |
| Dividends paid | $3.98M | $4.26M | $4.28M | $3.16M | $11.46M |
| Share buybacks | $8.36M | $19.97M | $0 | $2.50M | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.